0 23 eps expected for insys therapeutics inc insy 2


$-0.23 EPS Expected for INSYS Therapeutics, Inc. (INSY)


March 10, 2018 – By Dolores Ford



Investors sentiment increased to 1.25 in 2017 Q3. Its up 0.05, from 1.2 in 2017Q2. It increased, as 20 investors sold INSYS Therapeutics, Inc. shares while 20 reduced holdings. 19 funds opened positions while 31 raised stakes. 18.21 million shares or 3.74% more from 17.56 million shares in 2017Q2 were reported.

9,516 are owned by Tci Wealth Advisors Inc. Balyasny Asset Ltd Liability invested in 0.01% or 175,000 shares. Deutsche National Bank Ag has invested 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Cambridge Invest Incorporated holds 40,394 shares or 0% of its portfolio. Regal Invest Advisors owns 0.33% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 161,600 shares. Manufacturers Life Insurance Com The reported 24,726 shares. California State Teachers Retirement System reported 37,779 shares. Raymond James & Associate has invested 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Grp One Trading Lp holds 0% or 14,196 shares. Gam Holdings Ag invested in 83,940 shares. Jacobs Levy Equity Management Inc accumulated 0% or 14,640 shares. 158,021 were accumulated by Financial Bank Of Mellon Corporation. Janney Montgomery Scott Limited Liability Corp has 15,150 shares for 0% of their portfolio. The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Credit Suisse Ag reported 33,211 shares or 0% of all its holdings.

Analysts expect INSYS Therapeutics, Inc. (NASDAQ:INSY) to report $-0.23 EPS on April, 2.They anticipate $0.22 EPS change or 2,200.00 % from last quarter’s $-0.01 EPS. After having $-0.25 EPS previously, INSYS Therapeutics, Inc.’s analysts see -8.00 % EPS growth. The stock decreased 2.48% or $0.19 during the last trading session, reaching $7.48. About 1.35 million shares traded. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 5.69% since March 10, 2017 and is downtrending. It has underperformed by 22.39% the S&P500.



INSYS Therapeutics, Inc. (NASDAQ:INSY) Ratings Coverage

Among 6 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Insys Therapeutics had 22 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 4 by Jefferies. The stock has “Hold” rating by Piper Jaffray on Tuesday, July 25. RBC Capital Markets maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) on Thursday, June 1 with “Buy” rating. As per Friday, October 27, the company rating was maintained by RBC Capital Markets. The rating was maintained by Oppenheimer on Tuesday, August 4 with “Hold”. On Wednesday, February 24 the stock rating was maintained by Jefferies with “Buy”. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, December 21 report. The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The rating was maintained by RBC Capital Markets on Thursday, August 3 with “Buy”. Janney Capital initiated INSYS Therapeutics, Inc. (NASDAQ:INSY) rating on Thursday, April 14. Janney Capital has “Buy” rating and $22 target.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $548.41 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

More notable recent INSYS Therapeutics, Inc. (NASDAQ:INSY) news were published by: Globenewswire.com which released: “INSYS Therapeutics to Report Fourth Quarter 2017 Results on March 8” on February 23, 2018, also Globenewswire.com with their article: “INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results” published on March 08, 2018, Globenewswire.com published: “INSYS Therapeutics to Present at RBC Healthcare Conference” on February 20, 2018. More interesting news about INSYS Therapeutics, Inc. (NASDAQ:INSY) were released by: Bloomberg.com and their article: “Ivy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks” published on March 09, 2018 as well as Globenewswire.com‘s news article titled: “INSYS Therapeutics Initiates Phase 3 Clinical Trial of Cannabidiol (CBD) Oral …” with publication date: March 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Back To Top